New Delhi: Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating `diabetic dyslipidemeia` for launch, the company said in a filing to BSE.Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."
Pune blast: ATS tracking online chats of IM terrorists
Devotees throng Mathura on the occassion of Guru Purnima
Shirdi Sai Baba is not God or Guru, says Shankaracharya
UPSC aspirants protest outside Rajnath Singh`s residence